ResearcherIndian Institute of Technology BhubaneswarNo recent work listed

Anasuya Roychowdhury

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3735-3021; OpenAlex author ID A5077908783. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2022: 2 papers

Papers 2

ATAD2 suppression enhances the combinatorial effect of gemcitabine and radiation in pancreatic cancer cells. Last author DOI 10.1016/j.bbrc.2022.10.021 ↗
MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2. Last author DOI 10.1016/j.lfs.2022.120592 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Madhuri Dutta · 2 shared papers, 2022 · strength 0.39
- Paper ATAD2 suppression enhances the combinatorial effect of gemcitabine and radiation in pancreatic cancer cells. DOI 10.1016/j.bbrc.2022.10.021 ↗
- Paper MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2. DOI 10.1016/j.lfs.2022.120592 ↗
Debasish Mohapatra · 2 shared papers, 2022 · strength 0.39
- Paper ATAD2 suppression enhances the combinatorial effect of gemcitabine and radiation in pancreatic cancer cells. DOI 10.1016/j.bbrc.2022.10.021 ↗
- Paper MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2. DOI 10.1016/j.lfs.2022.120592 ↗
Shantibhusan Senapati · 2 shared papers, 2022 · strength 0.39
- Paper ATAD2 suppression enhances the combinatorial effect of gemcitabine and radiation in pancreatic cancer cells. DOI 10.1016/j.bbrc.2022.10.021 ↗
- Paper MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2. DOI 10.1016/j.lfs.2022.120592 ↗
Biswajit Das · 1 shared paper, 2022 · strength 0.19
- Paper MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2. DOI 10.1016/j.lfs.2022.120592 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.